Faron Pharmaceuticals
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | 14.4m | 31.0m | 12.9m |
| % growth | - | - | - | - | - | 115 % | (59 %) |
| EBITDA | (16.3m) | (20.6m) | (27.0m) | (28.4m) | (21.0m) | 1.9m | (33.9m) |
| % EBITDA margin | - | - | - | - | (146 %) | 6 % | (264 %) |
| Profit | (16.9m) | (21.2m) | (28.7m) | (30.9m) | (26.0m) | (3.0m) | (33.9m) |
| % profit margin | - | - | - | - | (181 %) | (10 %) | (264 %) |
| EV / revenue | - | - | - | - | 18.6x | 6.9x | 19.8x |
| EV / EBITDA | -8.1x | -7.9x | -7.6x | -8.7x | -12.8x | 111.9x | -7.5x |
| R&D budget | 13.9m | 17.4m | 20.7m | 19.5m | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
€6.0m | Grant | ||
| N/A | €14.1m Valuation: €84.9m | IPO | |
$1.7m | Grant | ||
| N/A | £5.0m | Post IPO Equity | |
* | N/A | £10.0m | Post IPO Equity |
€2.5m | Grant | ||
* | €800k | Grant | |
€4.9m | Post IPO Equity | ||
€3.5m | Post IPO Equity | ||
$30.0m | Post IPO Debt | ||
* | €5.0m | Post IPO Equity | |
* | €12.0m | Post IPO Equity | |
* | N/A | €3.2m | Post IPO Convertible |
* | N/A | €4.8m | Private Placement VC |
* | N/A | €30.7m | Post IPO Equity |
| Total Funding | CAD23.4m | ||
Related Content
Recent News about Faron Pharmaceuticals
EditFaron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.
Keywords: Pharmaceuticals and Biotechnology, Biopharmaceutical Research, Cancer Immunotherapy, Cancer Immunotherapy Product, Clinical Stage, Novel Therapeutics, Organs Traumas, Pharmaceutical.